The FDA Commissioner Tried to Kill a Rare Disease Drug. It Didn't Work.
The FDA commissioner allegedly tried to personally reject KalVista's rare disease drug, an almost unheard-of level of political intervention in drug approvals. The drug got approved anyway, but the episode reveals a troubling pattern at Makary's FDA.
Imagine you're a student who aced every exam, turned in every assignment early, and then the principal personally walks into your classroom to fail you anyway. That's roughly what happened to KalVista Pharmaceuticals last year, according to a bombshell report from Endpoints News.
The outlet alleged that FDA Commissioner Marty Makary personally sought the rejection of KalVista's drug application for sebetralstat, an oral treatment for a painful rare disease called hereditary angioedema. If true, it would represent an extraordinary breach of how drug approvals are supposed to work in the United States. And it raises a question that's getting harder to ignore: is the FDA's drug review process becoming a political football?
The Drug That Shouldn't Have Been Controversial
Before we get into the drama, let's talk about what sebetralstat actually does. Hereditary angioedema (HAE) causes sudden, severe swelling episodes that can hit the face, hands, gut, or airway. These attacks are unpredictable, sometimes life-threatening, and historically could only be treated with injections or IV infusions.
Sebetralstat was designed to change that. It's the first oral, on-demand treatment for acute HAE attacks: a pill you can take when symptoms start instead of reaching for a needle. KalVista's phase 3 trial (called KONFIDENT) delivered positive results in February 2024, showing rapid symptom relief.
For the roughly 6,000 to 10,000 Americans living with HAE, this wasn't just a new option. It was a potential game-changer.
A Review That Went Off the Rails
The FDA accepted KalVista's application and set a PDUFA date (the agency's deadline to make a decision) of June 17, 2025. Everything looked clean. No unusual requests. No red flags from reviewers.
Then, four days before the deadline, KalVista dropped an unusual announcement: the FDA would not meet its own deadline. The reason? "Heavy workload and limited resources," according to the company. Critically, KalVista noted that the FDA had and had .
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
not requested additional data or studies
not raised safety, efficacy, or approvability concerns
That's like your teacher telling you they can't grade your test, but also confirming there's nothing wrong with your answers. Leerink analyst Joseph Schwartz called it the first delay he was aware of that was directly tied to FDA resource constraints. His team said they remained "confident in the eventual approval" of sebetralstat.
But Endpoints News, citing anonymous internal sources and internal messages, told a very different story.
The Commissioner Enters the Chat
According to Endpoints, Commissioner Makary personally sought to have KalVista's application rejected. This is not normal. It's not even close to normal.
FDA drug approvals are designed as a technical, scientific process. Career reviewers at the Center for Drug Evaluation and Research (CDER) evaluate the data, weigh the evidence, and make the call. The commissioner oversees the agency and sets broad policy, but doesn't typically wade into individual drug decisions. Think of it like a CEO who sets the company's strategy but doesn't personally approve every invoice.
When a commissioner does intervene in a specific case, it sends shockwaves. It suggests the decision is being driven by something other than the science; politics, ideology, or personal agenda. According to Endpoints' sources, senior officials pushed back on the alleged rejection effort, citing legal risk. The attempt reportedly did not stick.
HHS, for its part, denied the whole thing, calling the report "totally false and untrue." Makary himself had publicly insisted that drug reviews were not being compromised, saying, "The trains are running on time."
The Trains Were Not Running on Time
Whatever happened behind closed doors, sebetralstat was approved on July 3, 2025, roughly two weeks after the missed deadline. KalVista launched it under the brand name EKTERLY just four days later, on July 7. Since then, the drug has been approved in the European Union and Switzerland.
The pediatric program is also moving forward. KalVista's KONFIDENT-KID trial in children ages 2 to 11 reported positive interim data in December 2025, showing kids were able to dose within a median of 25 minutes after an attack began and experienced symptom relief within 1.5 hours. As of August 2026, six additional global regulatory submissions were under review.
So the story has a happy ending for patients. But it's the journey that should worry the biotech industry.
A Pattern, Not an Anomaly
The KalVista episode didn't happen in a vacuum. Throughout 2025 and 2026, Makary's FDA developed a reputation for inconsistent decision-making, particularly around rare disease therapies and specialty drugs.
The agency rejected Replimune's melanoma drug candidate, drawing major backlash from the oncology community. It asked uniQure for additional clinical research on a Huntington's disease therapy, despite earlier signals that accelerated approval was possible. In another head-scratcher, the FDA approved leucovorin for cerebral folate deficiency without clinical trial data while stopping short of approving it for autism.
Critics also pointed to process concerns beyond individual decisions. One report alleged that Makary and advisor Vinay Prasad issued new COVID-19 booster guidance without normal staff input or advisory committee review. Another said reviewers were blocked from voting on at least one drug under a new expedited-review program.
The overall pattern, according to stakeholders across the industry, was an FDA trying to balance faster approvals with stricter evidence demands. The execution, though, looked chaotic. Drugmakers and patient advocates said the unpredictability was creating real uncertainty about what it takes to get a drug approved.
Why This Matters Beyond One Drug
Drug development is already one of the longest, most expensive bets in business. Companies spend a decade and hundreds of millions of dollars to get a molecule to the FDA's doorstep. The entire system depends on the belief that the science determines the outcome, not who's sitting in the commissioner's office.
If that trust erodes, the consequences ripple outward. Investors price in political risk. Companies hesitate to pursue drugs for small patient populations where the commercial upside is already thin. And patients with rare diseases, the people who have the fewest options and the most to lose, end up waiting even longer.
KalVista's sebetralstat eventually made it through. But the fact that a first-in-class oral treatment for a serious rare disease reportedly had to survive a commissioner-level intervention just to reach patients? That's not a system working as designed. That's a warning sign.
The FDA's credibility is its most valuable asset. It's built on decades of rigorous, science-first review. Protecting that reputation isn't just good governance; it's a matter of public health. And right now, there are more questions than answers about whether that protection is holding.
4 min read
A Seal in South Australia Just Became a Pandemic Warning Sign
Australia just confirmed H5N1 bird flu in a local mammal for the first time: a long-nosed fur seal found on a South Australian beach. It's a quiet milestone with loud implications for pandemic preparedness, and it signals the virus is finding new footholds in the Southern Hemisphere.
